Traders Buy Large Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the target of unusually large options trading on Wednesday. Stock traders bought 50,051 call options on the stock. This is an increase of 298% compared to the typical daily volume of 12,577 call options.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $3.44 on Friday. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a twelve month low of $2.77 and a twelve month high of $7.18. The business has a 50-day moving average price of $3.26 and a 200-day moving average price of $3.85. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -2.87 and a beta of 1.05.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. The company had revenue of $6.47 million for the quarter, compared to analysts’ expectations of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm’s revenue was down 56.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.50) EPS. As a group, equities research analysts predict that Recursion Pharmaceuticals will post -1.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on RXRX. Morgan Stanley increased their price objective on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Bank of America lowered their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Finally, JPMorgan Chase & Co. lowered their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $8.10.

Insiders Place Their Bets

In related news, CEO Najat Khan sold 28,298 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $3.35, for a total value of $94,798.30. Following the transaction, the chief executive officer owned 2,262,085 shares in the company, valued at $7,577,984.75. The trade was a 1.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Ben R. Taylor sold 7,956 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total transaction of $26,970.84. Following the sale, the chief financial officer directly owned 1,180,318 shares in the company, valued at $4,001,278.02. This trade represents a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 96,254 shares of company stock valued at $320,369. 8.43% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its position in shares of Recursion Pharmaceuticals by 18.2% during the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after purchasing an additional 384,486 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Recursion Pharmaceuticals by 59.4% in the first quarter. Janus Henderson Group PLC now owns 220,309 shares of the company’s stock worth $675,000 after buying an additional 82,100 shares in the last quarter. California State Teachers Retirement System boosted its stake in Recursion Pharmaceuticals by 64.0% during the first quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock valued at $1,764,000 after buying an additional 224,332 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Recursion Pharmaceuticals by 7.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 219,998 shares of the company’s stock valued at $675,000 after buying an additional 15,049 shares in the last quarter. Finally, Themes Management Co LLC bought a new stake in Recursion Pharmaceuticals in the 1st quarter worth approximately $236,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.